|
In partnership with the academy, the company established a technological platform for DNA, subunit protein and vetorized vaccine development and takes promising research and early development candidates through pre-clinical regulatory requirements, formulation, pilot lot manufacturing process and clinical Phase I and II studies. 
Under the guidance of the Regulatory QA Group, the company has been developing numerous S.O.P.s to meet compliance with safety regulations and guidelines, recombinant organism (GMO) guidelines, current good manufacturing practices (cGMP) guidelines, including installation qualification (IQ), operational qualification (OQ) and validation of facilities & equipments.
| 
